RGO GER Week ended 31 Jul 2026

Weekly Investor Report

Regeneron Pharmaceuticals, Inc. · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 641.2 EUR
9.9% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is 4.3% above the Trend Line and sits at 48.8% of its 52-week range. The latest completed week returned 9.9%, after a 12.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal.

Setup score 41 out of 100
Latest Close 641.2 EUR 31 Jul 2026
1W Return 9.9% latest completed week
4W Return 12.1% short-term follow-through
12W Return 1.3% quarterly tape
Trend Breadth 0.0% 0 of 52 weeks active
Volume Ratio 0.9x vs 13-week average
What is working
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
  • Latest weekly return ranks in the strongest part of its sector group.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 9.9% Latest completed week; four-week move 12.1%. Indicator stack 0/69 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. News sentiment 51/100 20 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is 4.3% above the Trend Line and sits at 48.8% of its 52-week range. The latest completed week returned 9.9%, after a 12.1% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.1012-week average 0.03

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure2/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.10Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 12.1% over four weeks, 1.3% over 12 weeks, and -16.0% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W9.9%
4W12.1%
12W1.3%
26W4.0%
52W-16.0%
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.40Latest activity-pressure read.
Pressure change151.7%Four-week change in activity pressure.
Leadership-7.36Latest relative-leadership reading.
RS change62.6%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 94% Model confidence 90%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength32/100Blend of value, momentum, and quality. Underlying universe rank 69; rank 1 is best.
Value43/100Relative valuation strength. Underlying universe rank 58; rank 1 is best.
Quality73/100Profitability and accounting quality. Underlying universe rank 28; rank 1 is best.
Momentum15/100Medium-term price momentum. Underlying universe rank 86; rank 1 is best.
Growth32/100Revenue and earnings growth. Underlying universe rank 69; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Value-quality framework46/100Value and quality alignment from the Sharemaestro SVQF framework.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
13.8x
Price divided by trailing earnings.
Price / sales
4.1x
Market value relative to trailing revenue.
EV / EBITDA
10.6x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
6.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
84.5%
Gross profit retained from each unit of revenue.
Operating margin
25.7%
Operating profit retained from revenue.
Free-cash-flow margin
25.4%
Free cash flow generated from revenue.
Return on invested capital
9.2%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
1.0%
Latest one-year revenue growth.
EPS growth
5.9%
Latest one-year earnings-per-share growth.
Free-cash-flow growth
6.4%
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
0.4%
Cash dividends relative to market value.
Buyback yield
5.0%
Net share repurchases relative to market value.
Shareholder yield
5.4%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.0x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment51/100

Weighted news tone is neutral across 20 relevant articles.

3 positive · 16 neutral · 1 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-16.0%Distance below the 52-week high.
13-week volatility5.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2611 weeks finished lower.
Best week+9.9%Week of 31 Jul.
Worst week-13.4%Week of 22 May.
Latest week+9.9%Week of 31 Jul.

Shape of recent returns

Strong gains4
Modest gains7
Flat weeks4
Modest losses9
Sharp losses2
Recent vol5.3%13-week weekly-return volatility.
Base vol5.4%52-week weekly-return volatility.
Up/down split19/16Count of positive and negative weeks in the 52-week window.
Average skew3.7% / -5.0%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape34/100

Trend, activity pressure, participation, and risk combine to a 34/100 tape read.

 Indicator analysis14/100

Latest 12-week confirmation: trend 0/12, activity pressure 2/12, relative leadership 0/12.

Activity pressure 0.10; No reversal markers Factors41/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 8; Small Cap Core rank 54 SVQF46/100

Value and quality alignment from the Sharemaestro SVQF framework.

Composite rank 201.5 of 372 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment51/100

Weighted news tone is neutral across 20 relevant articles.

REGN UPCOMING DEADLINE: Levi & Korsinsky Alerts Regeneron Pharmaceuticals, Inc. Stockholders of Securities Class Action - Contact the Firm Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 2026641.2 EUR9.9%615.0 EUR727.3 EUR0.40-7.36167Off
24 Jul 2026583.4 EUR-2.2%615.6 EUR727.7 EUR0.06-14.39251Off
17 Jul 2026596.8 EUR3.0%618.3 EUR728.2 EUR-0.21-11.99242Off
10 Jul 2026579.3 EUR1.3%620.0 EUR728.6 EUR-0.50-15.81661Off
3 Jul 2026571.9 EUR2.5%621.7 EUR728.9 EUR-0.77-19.6688Off
26 Jun 2026558.2 EUR5.3%623.2 EUR729.5 EUR-0.93-18.627Off
19 Jun 2026530.0 EUR0.3%627.0 EUR730.0 EUR-0.95-24.18500Off
12 Jun 2026528.4 EUR-4.2%630.9 EUR731.2 EUR-0.92-23.9347Off
5 Jun 2026551.4 EUR4.1%633.1 EUR732.4 EUR-0.76-21.616Off
29 May 2026529.9 EUR-3.3%633.3 EUR733.3 EUR-0.47-26.16216Off
22 May 2026547.8 EUR-13.4%641.0 EUR734.3 EUR-0.29-23.55300Off
15 May 2026632.7 EUR0.0%648.2 EUR735.0 EUR-0.14-8.870Off
8 May 2026632.7 EUR0.0%652.5 EUR735.5 EUR-0.12-10.660Off
1 May 2026632.7 EUR0.0%656.9 EUR735.8 EUR-0.17-10.870Off
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.